Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study GroupRainer Porschen, Hans‐Joachim Schmoll, Hendrik‐Tobias Arkenau et al.|Journal of Clinical Oncology|2007Cited by 281
Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): Results of the safety and efficacy analysisHendrik‐Tobias Arkenau, Rainer Porschen, Stefan Kubicka et al.|Journal of Clinical Oncology|2005Cited by 42
Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal CancerHendrik‐Tobias Arkenau, Rainer Porschen, Ullrich Graeven et al.|Clinical Colorectal Cancer|2008Cited by 30
Intraperitoneal Bevacizumab (Bev) for Control of Malignant Ascites Due to Advanced-Stage Gastrointestinal Cancers (Gi): a Multicenter Double-Blind, Placebo (Pl)-Controlled, Randomized Phase Ii Study. Aio Sup-0108Karin Jordan, S. Hegewisch-Becker, Djordje Atanackovic et al.|Annals of Oncology|2014Cited by 0
In ReplyRainer Porschen, Hans‐Joachim Schmoll, Hendrik‐Tobias Arkenau et al.|Journal of Clinical Oncology|2007Cited by 0